Angio-Seal™
Vascular Closure Device

RESTICK
FOLLOWING INITIAL ANGIO-SEAL DEVICE USE SHOWN TO BE SAFE

Safety of Restick Confirmed by Clinical Study
The safety and efficacy of a restick of the same artery following an initial Angio-Seal™ Device deployment was evaluated in 181 patients.

PATIENTS
Patients were included in the study if they had an Angio-Seal™ Device deployment and subsequently underwent arterial access using the same artery that had previously been closed with an Angio-Seal™ Device within 90 days of the original device placement.

FINDINGS
“The major finding of this study is that arterial restick following initial Angio-Seal™ Device placement can be performed safely without dislodgment of the device and without significant vascular complications.

Moreover, arterial closure of the vessel can be performed safely with a variety of techniques, including a second Angio-Seal™ Device.”

1
Restick Labeling Approved for Angio-Seal™ Vascular Closure Device

Labeling has been approved confirming the safety of restick of the same artery following initial Angio-Seal™ Vascular Closure Device use.

“If repuncture at the same location of previous Angio-Seal™ Device use is necessary in < 90 days, reentry 1cm proximal to the previous access site can be performed safely, based on published medical literature.”

Vascular Complications (N = 181)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Number</th>
<th>Proportion</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large hematoma (≥ 10cm)</td>
<td>3</td>
<td>0.0166</td>
<td>0.0043 - 0.0515</td>
</tr>
<tr>
<td>Vessel occlusion</td>
<td>0</td>
<td>0</td>
<td>0 - 0.0259</td>
</tr>
<tr>
<td>Pseudoaneurysm</td>
<td>0</td>
<td>0</td>
<td>0 - 0.0259</td>
</tr>
<tr>
<td>AV fistulae</td>
<td>0</td>
<td>0</td>
<td>0 - 0.0259</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>0</td>
<td>0</td>
<td>0 - 0.0259</td>
</tr>
<tr>
<td>Vascular repair</td>
<td>0</td>
<td>0</td>
<td>0 - 0.0259</td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
<td>0</td>
<td>0 - 0.0259</td>
</tr>
</tbody>
</table>

Procedural Characteristics (N = 181)

<table>
<thead>
<tr>
<th>Days Post First Angio-Seal™ Device</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-7</td>
<td>81</td>
<td>(45%)</td>
</tr>
<tr>
<td>8-30</td>
<td>34</td>
<td>(19%)</td>
</tr>
<tr>
<td>31-90</td>
<td>66</td>
<td>(36%)</td>
</tr>
</tbody>
</table>

“To our knowledge, there are no published reports of attempts to reaccess an artery in which an Angio-Seal™ Device has been deployed, that have led to vascular compromise or loss of hemostasis.”¹

Atrial Fibrillation
Cardiac Rhythm Management
Cardiac Surgery
Cardiology
Neuromodulation

St. Jude Medical
14901 Deveau Place
Minnetonka, MN 55345
952 933 4700
952 933 0307 Fax

St. Jude Medical Europe, Inc.
The Corporate Village
Avenue Da Vinci laan, 11 - Box F1
B-1935 - Zaventem
Belgium
+32 2 774 68 11
+32 2 772 83 84 Fax

St. Jude Medical Brasil, Ltda.
Rua Frei, Caneca 1380-9°
A-CJ91/92
Sao Paulo - SP - Brasil
CEP 01307-002
+55 11 5080 5400
+55 11 5080 5423 Fax

St. Jude Medical (Hong Kong) Limited
Unit 2701-07, COSCO Tower
Grand Millenium Plaza
183 Queen’s Road
Central, Hong Kong
+852 2996 7688
+852 2956 0622 Fax

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use.

Indications: St. Jude Medical Angio-Seal™ Vascular Closure Device product family, including the STS Plus, VIP and Evolution platforms, is indicated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in patients who have undergone diagnostic angiography procedures or interventional procedures using an 8 French or smaller procedural sheath for the 8F Angio-Seal™ device and a 6 French or smaller procedural sheath for the 6F Angio-Seal™ device. The Angio-Seal™ STS Plus, VIP and Evolution platform devices are also indicated for use to allow patients who have undergone diagnostic angiography to safely ambulate as soon as possible after sheath removal and device placement, as well as to allow patients who have undergone an interventional procedure to safely ambulate after sheath removal and device placement. Possible adverse events for vascular closure devices include, but are not limited to: bleeding or hematoma, AV fistula or pseudoaneurysm, infection, allergic reaction, foreign body reaction, inflammation, or edema.

Angio-Seal, ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2008 St. Jude Medical, Inc. All rights reserved.

Item 41664 Rev.-B